Table 2.
Renal features and treatment at baseline and at the end of follow-up
| Pt | At RTX Initiation (Baseline)
|
CD19 + Depleted M1 | F-Up M | After RTX (End of Follow-Up)
|
Response M12/End | ||||
|---|---|---|---|---|---|---|---|---|---|
| Pu (g/d)/Alb (g/l)/eGFR (ml/min/1.73 m2) | KB | IS | Pu (g/d)/Alb (g/L)/eGFR (ml/min/1.73 m2) | KB Date/Result | IS | ||||
| 1 | 3/27/120 | IVG(10/0) | Cs (0.5) | - | 23 | 3/17/107 | M14:IVG + V (3/1) | Cs (0. 2) MMF | NR/NR |
| 2a | 5/28/74 | IVG + V(10/1) | Cs (1)b HCQ | + | 48 | 0.3/37/135 | M26:IVS + V (1/4) | Cs (0.1) HCQ | NR/CR |
| 3 | 5/19/71 | IVS + V(6/7) | Cs (0.1)b HCQ | na | 20 | 0.2/31/119 | Cs (0.1) MMF HCQ | PR/CR | |
| 4 | 04/11/58 | IVG + V(8/8) | Cs (0.3)b MMF | - | 13 | na/28/HD | M2:IVG (8/10) | Cs (0.1) CYP (4) | HD/HD |
| 5a | 5/24/105 | IVSc | Cs (1)b | + | 21 | 1/36/83 | Cs (0.1) | PR/PR | |
| 6a | 6/26/52 | IVG + V(11/6) | Cs (1)b | + | 37 | 0,5/40/82 | M37:III (0/3) | Cs (0.2) | PR/CR |
| 7 | 0.5/40/150 | IVS(6/2) | Cs (0.3) MMF | + | 42 | 0/40/154 | M16:III + V (2/1) | Cs (0.1) AZA HCQ | PR/CR |
| 8 | 9/14/16 | IVG(10/8) | Cs (0.6)b | - | 21 | na/14/HD | Cs (0.2) | HD/HD | |
| 9a | 7/20/46 | IVS(11/4) | Cs (1)b HCQ | + | 51 | 0.5/34/52 | M5:IVS (2/8) | Cs (0.1) | PR/PR |
| 10 | 3/28/HD | IVGc | Cs (1)b CYP (4) | na | 31 | na/35/HD | Cs (0.1) | HD/HD | |
| 11 | 3/20/HD | IVG(13/6) | Cs (1)b CYP (4) | na | 31 | na/35/HD | Cs (0.2) AZA HCQ | HD/HD | |
| 12 | 1.5/29/47 | IVG(7/3) | Cs (1)b CYP (3) | + | 17 | 0/46/77 | Cs (0.2) MMF HCQ | CR/CR | |
| 13a | 5/23/66 | Vd | Cs (0.7)b HCQ | + | 19 | 4/25/65 | Cs (0.4) HCQ MMF | NR/NR | |
| 14 | 9/19/102 | V | Cs (0.2) MMF HCQ | - | 12 | 05/11/88 | Cs (0.1) CSA HCQ | NR/NR | |
| 15a | 4/26/127 | Vd | Cs (0.5)b | + | 33 | 0/35/122 | AZA | CR/CR | |
| 16a | 8/18/133 | Vd | Cs (1.5) | - | 10e | 4/24/53 | M3:III + V (8/0) | Cs (0.5) CYP (2) | NR |
| 17a | 7/22/147 | V | - | + | 13 | 0.3/33/116 | — | PR/CR | |
| 18a | 11/20/90 | IVG + V(7/4) | Cs (0.25) | + | 27 | 1/35/102 | M13:IVG + V (5/6) | Cs (0.06) HCQ | PR/PR |
| 19 | 7/23/9 | IVc | Cs (1)b HCQ | + | 14 | 1.6/37/16 | M7:IVG (9/8) | Cs (0.4) HCQ MMF | PR/PR |
| 20a | 25/22/26 | IVG + V(8/6) | Cs (1.2) | + | 24 | 1/35/52 | Cs (0.2) MMF | PR/PR | |
Pt, patient; RTX, rituximab; IS; immunosuppressive therapy; Pu, proteinuria; Alb, albuminemia; eGFR, estimated glomerular filtration rate; KB, kidney biopsy; M1, one month after RTX initiation; F-up, follow-up; M, months; Cs, corticosteroids; Cs(X), dose of oral Cs in mg/kg/day; HCQ, hydroxyhloroquine; MMF, mycofenolate mofetil; CYP, cyclophosphamide; AZA, azathioprine; CSA, cyclosporine A; KB interpretation: S, segmental; G, global; (activity index /24; chronicity index /12); na, not available; NR, absence of renal remission; CR, complete renal remission, PR, partial renal remission; HD, haemodialysis.
RTX maintenance therapy.
High-dose intravenous corticosteroid injection.
Kidney biopsy specimen not available for blinded reading.
Kidney biopsy performed more than 3 months before RTX initiation.
Deceased.